when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Sustol

drug

granisetron ER

Marketedupdated 3mo ago

by Heron Therapeutics Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 2

tagApproval12 co-mentions · 3 sources
drugSUSTOL12 co-mentions · 3 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 6 investigational indications.

all catalysts(3)

approval · 3

$HRTX0.5114+3.06%

SUSTOL (GRANISETRON) — FDA approval

$HRTX0.5114+3.06%

SUSTOL (GRANISETRON) — FDA approval

$HRTX0.5114+3.06%

SUSTOL (GRANISETRON) — FDA approval

Trials studying granisetron ER

phase1Staccato® Granisetron Single Dose PKcompletedn=36
phase4Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)completedn=414
phase1Granisetron 1 mg Tablets, Non-fastingcompletedn=80
phase1Granisetron 1 mg Tablets Under Fasting Conditionscompletedn=40
phase1Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Yearswithdrawn
phase1Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Yearswithdrawn
phase1An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetroncompletedn=60
phase1Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Yearscompletedn=19

more trials →

News(0)

no news has mentioned this drug yet

brand

Sustol

generic

granisetron

MOA

12.1 Mechanism of Action Granisetron is a selective 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , 5-HT 2 ; for alpha 1- , alpha 2- , or beta-adrenoreceptors; for dopamine-D 2 ; or for histamine-H 1 ; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT 3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT 3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT 3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.

indication

Chemotherapy Induced Nausea and Vomiting

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?